Nutriband Inc. to Showcase AVERSA(TM) Technology at Emerging Growth Conference

Nutriband Inc. (NASDAQ: NTRB), a company at the forefront of developing innovative transdermal pharmaceutical products, is set to make a significant presentation at the Emerging Growth Conference on August 20, 2025. The event will feature Chairman Serguei Melnik, who will provide a live, interactive presentation on the company's advancements, particularly focusing on its AVERSA(TM) abuse-deterrent technology. This technology represents a pivotal development in the pharmaceutical industry, offering a solution to the abuse, misuse, diversion, and accidental exposure of drugs with high abuse potential.

The AVERSA(TM) technology, which can be integrated into any transdermal patch, is designed to deter the abuse of potent drugs such as fentanyl. Nutriband's participation in the Emerging Growth Conference underscores the importance of its work in addressing a critical public health issue. The conference provides a platform for Nutriband to engage with shareholders and the investment community, offering insights into how its technology could shape the future of drug delivery systems.

For those interested in learning more about Nutriband's initiatives and its AVERSA(TM) technology, additional information is available at https://ibn.fm/dhj3J. The company's commitment to innovation in the biomedical sector is further detailed in its newsroom at https://ibn.fm/NTRB, where updates and news related to NTRB are regularly posted.

Nutriband's presentation at the Emerging Growth Conference is a testament to the company's role in advancing pharmaceutical technology. By focusing on abuse-deterrent formulations, Nutriband is addressing a significant challenge in medication safety and efficacy, marking an important step forward in the fight against drug abuse.